Seres Therapeutics, Inc. MCRB
1.44 USD -0.06 (-4.00%)
Nov 12, 2026, 11:19 AM EST
1.30 Day range 1.48
1.30 52-week range 29.98
- YTD
- -90.32%
- 1 year
- -91.01%
News
benzinga.com Seres Therapeutics Q3 EPS $(1.63) Misses $(1.00) Estimate, Sales $593.000K Miss $6.350M Estimate Seres Therapeutics (NASDAQ:MCRB) reported quarterly losses of $(1.63) per share which missed the analyst consensus estimate of $(1.00) by 63 percent. This is a 273.4 percent decrease over earnings of…
benzinga.com Seres Therapeutics Announces Publication Of Results From Phase 1b Clinical Study Of SER-155 In Adults Undergoing Allogeneic Hematopoietic Cell Transplantation In Nature Medicine Issue Peer-reviewed publication reports a 77% relative risk reduction in bloodstream infections and significantly lower systemic antibiotic exposure with SER-155 compared with placeboTranslational data…
benzinga.com On, October 22, 2026, Seres Therapeutics' CFO Marella Thorell Resigned Effective November 15, 2026 On October 22, 2026, Marella Thorell, Executive Vice President and Chief Financial Officer of Seres Therapeutics, Inc. (the "Company"), resigned from her positions as Executive Vice President and…
benzinga.com Seres Therapeutics To Present Preclinical Data Supporting Development Of SER-428, Investigational Oral Liquid LBP To Reduce Risk Of Bloodstream Infections In Critically Ill Patients, At IDWeek 2026 Novel oral liquid formulation of SER-428 is designed for patients who cannot take oral capsules, including critically ill patients receiving nutrition via feeding tubeSER-428 significantly reduced…
benzinga.com Seres Therapeutics Files Prospectus for Up To $300M Offering Of Common Stock, Preferred Stock, Debt, Warrants And Units SERES THERAPEUTICS, INC.$300,000,000Common StockPreferred StockDebt SecuritiesWarrantsUnitsWe may offer and sell up to $300,000,000 in the aggregate of the securities identified above from time to…
benzinga.com Seres Therapeutics Q2 EPS $0.47 Beats $(2.19) Estimate, Sales $736.000K Beat $179.000K Estimate Seres Therapeutics (NASDAQ:MCRB) reported quarterly earnings of $0.47 per share which beat the analyst consensus estimate of $(2.19) by 121.56 percent. This is a 120.7 percent increase over losses of…
benzinga.com Seres Therapeutics Posts Early Data for Cancer Therapy Complication Seres Therapeutics reported early SER-155 data, with 80% of patients achieving steroid-free clinical response by Day 15.- benzinga.com Seres Therapeutics Announces Top-Line Results From An IST Evaluating SER-155 In Patients With irEC; SER-155 Well Tolerated, With No Drug-Related Serious Adverse Events Observed The study (NCT06801067), conducted at MSK, by Principal Investigator David Faleck, M.D., Director of Inflammatory and Immune-Related Bowel Diseases, evaluated SER-155 in 15 patients with…
- benzinga.com Seres Therapeutics To Host July 8 Webcast To Discuss Top-Line Results From A Trial Evaluating SER-155 In Patients With Immune Checkpoint Inhibitor-Related Enterocolitis The IST was conducted at Memorial Sloan Kettering Cancer Center, with which Seres has a long history of collaboration, by Principal Investigator David Faleck, M.D., Director of Inflammatory and…
benzinga.com This Insulet Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday Wall Street analysts changed outlook on top names, including MCRB, SAFX. See analyst ratings page for full coverage.- benzinga.com HC Wainwright & Co. Initiates Coverage On Seres Therapeutics with Buy Rating, Announces Price Target of $12 HC Wainwright & Co. analyst Matthew Keller initiates coverage on Seres Therapeutics (NASDAQ:MCRB) with a Buy rating and announces Price Target of $12.
benzinga.com Seres Therapeutics Announces Balance Sheet Transactions; Nestle To Pay Company $25 M In Two Installments To Buy Out Sales Milestone Payments Seres Therapeutics, Inc. (NASDAQ:MCRB), ("Seres" or the "Company"), a leading live biotherapeutics company, today announced two transactions to strengthen its balance sheet and extend its expected…- benzinga.com Seres Therapeutics Q1 EPS $(2.08) Misses $(1.88) Estimate, Sales $358.000K Seres Therapeutics (NASDAQ:MCRB) reported quarterly losses of $(2.08) per share which missed the analyst consensus estimate of $(1.88) by 10.64 percent. This is a 155.47 percent decrease over…
- benzinga.com Seres Therapeutics Presents New Preclinical Data To Support Design, Potential Of SER-603 Cultivated Live Biotherapeutic Candidate For Inflammatory Bowel Disease Seres Therapeutics, Inc. (NASDAQ:MCRB) (Seres or the Company), a leading live biotherapeutics company, today announced new preclinical data supporting the design and potential of SER-603, a…
- benzinga.com Seres Therapeutics Presents New Preclinical Data Supporting Design And Potential Of SER-603, Next-Gen Cultivated Live Biotherapeutic Candidate For Inflammatory Bowel Disease, At DDW 2026 Data highlight both SER-603's rational design that targets microbial functions linked to mucosal healing and gastrointestinal inflammation in IBD, as well as the advancement of microbiome-based…
- benzinga.com Seres Therapeutics Announces Three Presentations To Take Place At The 2026 European Society Of Clinical Microbiology And Infectious Diseases Global Congress, April 17-21 Presentations DetailsPoster Presentation (Abstract 1726)Title: Effect of investigational, live biotherapeutic, SER-155, on gastrointestinal (GI) microbiome composition in adults receiving allogeneic…
benzinga.com Earnings Scheduled For March 12, 2026 - benzinga.com Seres Therapeutics Q4 EPS $(1.76) Beats $(2.22) Estimate, Sales $438.000K Miss $5.875M Estimate Seres Therapeutics (NASDAQ:MCRB) reported quarterly losses of $(1.76) per share which beat the analyst consensus estimate of $(2.22) by 20.61 percent. This is a 10 percent decrease over losses of…
- benzinga.com Seres Therapeutics Appoints Richard N. Kender As Executive Chair And Interim CEO Seres Therapeutics, Inc. (NASDAQ:MCRB), (Seres or the Company), a leading live biotherapeutics company, today announced the appointment of Richard N. Kender as Executive Chair and Interim Chief…
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session 
benzinga.com Seres Therapeutics Pauses Key Drug Study, Cuts Jobs To Save Cash Seres stock drops after pausing a key drug study and cutting 30% of staff. The company shifts focus to early-stage programs while seeking funding, extending cash runway into 2026.- benzinga.com Seres Therapeutics Finalizes Protocol For Phase 2 Study Of SER-155 In Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant With FDA Seres has finalized the protocol for the Phase 2 study of SER-155 in patients undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) with the FDA and has advanced key study startup…
- benzinga.com Seres Therapeutics Publishes New Data In Nature Medicine And Journal Of Infectious Diseases Supporting VOWST Mechanism And Broader Live Biotherapeutics Platform Data demonstrate clinical translation of VOWST mechanisms of action in both first and multiply recurrent CDI patientsSeres MbTx® platform provides high-resolution functional biological understanding…
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session 
benzinga.com Earnings Scheduled For November 5, 2025 - benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
benzinga.com Why Robinhood Shares Are Trading Higher By Over 7%; Here Are 20 Stocks Moving Premarket 
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session - benzinga.com Earnings Scheduled For August 6, 2025
benzinga.com Uber To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Thursday 
benzinga.com Earnings Scheduled For May 7, 2025 
benzinga.com Quest Diagnostics Posts Better-Than-Expected Earnings, Joins Pentair, 3M, Danaher And Other Big Stocks Moving Higher On Tuesday - benzinga.com Earnings Scheduled For March 13, 2025
- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
- benzinga.com Earnings Scheduled For November 13, 2024
- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
benzinga.com Why GameStop Shares Are Trading Lower By Over 22%? Here Are Other Stocks Moving In Friday's Mid-Day Session - benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
- benzinga.com Why Upstart Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
- benzinga.com Earnings Scheduled For March 5, 2024 Companies Reporting Before The Bell • NIO (NYSE:NIO) is estimated to report quarterly loss at $0.51 per share on revenue of $2.29 billion.
- benzinga.com Why Fortinet Shares Are Trading Lower By Around 17%? Here Are Other Stocks Moving In Friday's Mid-Day Session Gainers Benson Hill, Inc. (NYSE: BHIL) shares jumped 48.1% to $0.3740.
- benzinga.com Earnings Scheduled For November 2, 2023 Companies Reporting Before The Bell • AudioCodes (NASDAQ:AUDC) is estimated to report quarterly earnings at $0.18 per share on revenue of $61.52 million.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday Tuesday saw 132 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday On Thursday, 369 companies hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday On Wednesday, 311 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday On Tuesday, 647 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 369 companies set new 52-week lows.